Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
129 hedge funds and large institutions have $1.8B invested in Centessa Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 15 closing their positions.
107% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 15
17% more funds holding in top 10
Funds holding in top 10: 12 → 14 (+2)
13% more funds holding
Funds holding: 114 → 129 (+15)
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
0.58% less ownership
Funds ownership: 94.36% → 93.79% (-0.58%)
14% less capital invested
Capital invested by funds: $2.08B → $1.8B (-$286M)
80% less call options, than puts
Call options by funds: $2.37M | Put options by funds: $11.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$66.3M |
| 2 |
Holocene Advisors
New York
|
+$36.9M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30M |
| 4 |
Janus Henderson Group
London,
|
+$16.6M |
| 5 |
Morgan Stanley
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
-$65.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$54.1M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$27.3M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$22.6M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.7M |
CNTA Hedge Fund Activity: Q1 2025 in Review
129 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2025, worth a combined $1.8B — down 14% from $2.08B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CNTA positions and 15 closed out — a net gain of 16 holders — while 42 added to existing stakes and 38 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $66.3M. The largest seller was Vida Ventures Advisors, exiting entirely with an estimated $65.9M sold.
- 129 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2025, up from 114 in Q4 2024.
- Funds reported $1.8B of Centessa Pharmaceuticals stock for Q1 2025, down 14% quarter-over-quarter.
- 31 funds opened new Centessa Pharmaceuticals positions in Q1 2025 and 15 closed out, a net change of +16 holders.
- The largest Centessa Pharmaceuticals buyer in Q1 2025 was Avoro Capital Advisors, an estimated $66.3M added.
- The largest Centessa Pharmaceuticals seller in Q1 2025 was Vida Ventures Advisors, an estimated $65.9M sold.
Based on aggregated 13F filings for Q1 2025.